AS · est 2017TromsøUnder liquidationParent · 1 subsidiary
Brreg · companies
headcount series appears after two register changes
Roles from Brreg, shown for business contact only. No birth date is shown or exported (purpose limitation, GDPR Art. 6(1)(f)).
Brreg · company_people
3 registered roles
| Styrets leder | Karl Johan Jakola Multiple boards | 2026-06-17 | |
| Styremedlem | Sveinung Hole Multiple boards Serial CEO | 2026-06-17 | |
| Styremedlem | Søren Weis Dahl Multiple boards | 2025-07-11 |
NOK, amounts in thousands
| 2024 | 2025 | ||
|---|---|---|---|
| Revenue | |||
| Operating result | −71 | −71 | |
| Result before tax | −2 323 | ||
| Net result | −2 323 | ||
| Total assets | 44 | ||
| Equity | −156 |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Operating result | −71 | −71 | |||||
| Result before tax | −2 323 | ||||||
| Net result | −2 323 | ||||||
| Total assets | 44 | ||||||
| Equity | −156 |
Regnskapsregisteret · company_revenue · FY2025 (company)
register ledger · money
| 2026-07-09 | reg | accounts_filed: sisteInnsendteAarsregnskap | 2024 -> 2025 |
| 2024 | 2025 | ||
|---|---|---|---|
| NORINNOVA INVEST AS | 11 | 11 | — |
| SARSIA SEED AS | 6 | 6 | — |
| TROND MOHN FORSKNINGSSTIFTELSE | 16 | 16 | — |
| NORINNOVA AS | 5 | 5 | — |
| UNIVERSITETSSYKEHUSET NORD-NORGE HF | 5 | 5 | — |
| KRAKR AS | 2 | 2 | — |
| CAERUS CAPITAL AS | 1 | 1 | — |
| INVEN2 AS | 1 | 1 | — |
| PHARMAPATENT AS | 0 | 0 | — |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| NORINNOVA INVEST AS | 31 | 11 | 11 | 11 | 11 | 11 | — |
| SARSIA SEED AS | 19 | 6 | 6 | 6 | 6 | 6 | — |
| TROND MOHN FORSKNINGSSTIFTELSE | 16 | 16 | 16 | 16 | 16 | 16 | — |
| NORINNOVA AS | 9 | 5 | 5 | 5 | 5 | 5 | — |
| UNIVERSITETSSYKEHUSET NORD-NORGE HF | 6 | 5 | 5 | 5 | 5 | 5 | — |
| KRAKR AS | 2 | 2 | 2 | 2 | 2 | 2 | — |
| CAERUS CAPITAL AS | 1 | 1 | 1 | 1 | 1 | 1 | — |
| INVEN2 AS | 1 | 1 | 1 | 1 | 1 | 1 | — |
| PHARMAPATENT AS | 0 | 0 | 0 | 0 | 0 | 0 | — |
Aksjonærregisteret · company_ownership · 2025 · both directions
| 2024 | 2025 | 2026 | |
|---|---|---|---|
| auditor — | |||
| accountant FETT ØKONOMI AS 2026-06-23 | ● |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|
| auditor — | |||||||
| accountant FETT ØKONOMI AS 2026-06-23 | ● |
Brreg · company_org_roles
No recorded tender wins.
Relevant open tenders — matched · NACE 21.200 ↔ CPVsubscribers sharpen matches with per-company keywords
open-tender matching (NACE ↔ CPV) awaits Intelligo's open-tenders view
Doffin/TED · company_tender_wins · 2026-08-19
No job ads on record in the last 12 months.
NAV Arbeidsplassen · company_job_ad_months
Group revenue —Group net kr -2.44MTenders won 0Rolled up across the parent + 1 subsidiary — Prophylix AS alone is —.
rollup estimate · filed konsernregnskap not yet in Intelligo
| Prophylix AS | 100% | Manufacture of pharmaceutical preparations |
Aksjonærregisteret · company_ownership · 2025 · both directions
This company's annual report has not been read yet. The filed figures above come from the accounts form; everything the board wrote around them is in the PDF, which is read on request.
Regnskapsregisteret (årsberetning) · company_annual_reports
registered 2017-12-11audit opt-out 2025-07-30
Brreg · companies
register ledger · 2 events
| 2026-07-09 | reg | accounts_filed: sisteInnsendteAarsregnskap | 2024 -> 2025 |
| 2026-06-19 | reg | liquidation: underAvvikling | False -> True |
Skiwo · company_events